Mondelez pursues Hershey’s acquisition to shore up chocolate business: The CPG company hopes the second time’s the charm as it looks to offset skyrocketing cocoa costs and capitalize on growth opportunities.

Ozempic is becoming cheaper for Medicare beneficiaries: Falling prices are welcome news for seniors’ wallets. But a new proposal to expand access to GLP-1s for Medicare members could threaten the federal health insurance program itself.

From the rise of sophisticated AI-driven tools to new policies reshaping data privacy and competition, 2025 promises to be a year of relentless change. Companies that adapt will thrive, while others risk being left behind in a swiftly moving market.

Eli Lilly’s GLP-1 medication shortage ends: The host of players who offer compounded versions of the blockbuster drugs don’t have to worry—yet.

23andMe’s board resigns: After years of ill-fated endeavors, the en masse resignation marks the latest blow to 23andMe, which has been hemorrhaging cash and yet to turn a profit.

Kourtney Kardashian’s Lemme rolls out “GLP-1” weight loss supplement: The move is ingenious from a marketing perspective. But the brand could find itself in drugmakers’ crosshairs with already confusing marketing about the supplement’s key ingredient.

Both retailers used generative AI to improve employee productivity in Q2—Walmart leveraged the tech to improve its product catalog and Target used it to enhance in-store employee tools. Target’s curbside pickup service helped it grow digital comparable sales 8.7% YoY, while Walmart’s marketplace and sales of GLP-1 drugs contributed to its 4.2% comp sales growth YoY.

WeightWatchers enters the Rx business for obesity: Its acquisition of medication-based weight loss program Sequence signals an emerging digital health market trend—but consumers must be cautious of telehealth startups' claims.